Israel - anglès - Ministry of Health

bioavenir ltd, israel - remifentanil as hydrochloride - powder for solution for injection - remifentanil as hydrochloride 2 mg/vial - remifentanil - remifentanil bioavenir is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision .remifentanil bioavenir is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.

Israel - anglès - Ministry of Health

bioavenir ltd, israel - remifentanil as hydrochloride - powder for solution for injection - remifentanil as hydrochloride 5 mg - remifentanil - remifentanil bioavenir is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision .remifentanil bioavenir is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - alfentanil hydrochloride, quantity: 1.0876 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - alfentanil gh injection is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil gh injection is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil gh injection is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil gh injection or by adapting the infusion rate.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - alfentanil hydrochloride, quantity: 5.438 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - alfentanil gh injection is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil gh injection is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil gh injection is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil gh injection or by adapting the infusion rate.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - remifentanil hydrochloride 1.097mg equivalent to 1 mg remifentanil;   - powder for injection - 1 mg - active: remifentanil hydrochloride 1.097mg equivalent to 1 mg remifentanil   excipient: glycine hydrochloric acid - remifentanil-aft is indicated as an analgesic agent: · for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery · for the continuation of analgesia in the immediate post-operative period during transition to longer acting analgesia · for the provision of analgesia and sedation in mechanically ventilated intensive care patients.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - remifentanil hydrochloride 2.194mg equivalent to 2 mg remifentanil;   - powder for injection - 2 mg - active: remifentanil hydrochloride 2.194mg equivalent to 2 mg remifentanil   excipient: glycine hydrochloric acid - remifentanil-aft is indicated as an analgesic agent: · for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery · for the continuation of analgesia in the immediate post-operative period during transition to longer acting analgesia · for the provision of analgesia and sedation in mechanically ventilated intensive care patients.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - remifentanil hydrochloride 5.485mg equivalent to 5 mg remifentanil;   - powder for injection - 5 mg - active: remifentanil hydrochloride 5.485mg equivalent to 5 mg remifentanil   excipient: glycine hydrochloric acid - remifentanil-aft is indicated as an analgesic agent: · for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery · for the continuation of analgesia in the immediate post-operative period during transition to longer acting analgesia · for the provision of analgesia and sedation in mechanically ventilated intensive care patients.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - alfentanil hydrochloride, quantity: 5.438 mg (equivalent: alfentanil, qty 5 mg) - injection, solution - excipient ingredients: sodium chloride; dilute hydrochloric acid; water for injections - alfentanil-hameln is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil-hameln is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil-hameln is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil-hameln or by adapting the infusion rate.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - alfentanil hydrochloride, quantity: 1.0876 mg (equivalent: alfentanil, qty 1 mg) - injection, solution - excipient ingredients: sodium chloride; dilute hydrochloric acid; water for injections - alfentanil-hameln is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil-hameln is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil-hameln is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil-hameln or by adapting the infusion rate.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - erythromycin lactobionate, quantity: 1515 mg (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - indications as at 1 november 2002: oral erythromycin is not considered to be the antibiotic of choice in severely ill patients. erythrocin-i.v. (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae). respiratory tract infections due to mycoplasma pneumoniae. skin and skin structure infections caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). diphtheria - as an adjunct to diphtheria antitoxin in infections due to corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. acute pelvic inflammatory disease caused by neisseria gonorrhoeae: erythrocin-i.v. (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for t. pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. legionnaires' disease caused by legionella pneumophila. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.